Loading…
← CockpitCompetitor Analysis › 2367.HK Giant Biogene Holding Co. Ltd.Open in the cockpit ↗

Giant Biogene Holding Co. Ltd.2367.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Consumer Staples›Household/Personal Care

Chinese biotech skincare company specializing in recombinant collagen skincare and medical dressing products, under the Kefumei brand.

≈ A Chinese bio-skincare innovatorMomentum weak 20
Mkt cap
$2.47B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$13.1M
20-day average traded
Fwd P/E
8.6×
forward earnings
ROIC−WACC
+58.4 pp
WACC 9.8%
Hurdle
-46 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · HKDHK$19.13
1D-6.1%
1W-10.2%
1M-16.8%
3M-32.7%
6M-31.7%
YTD-42.5%
1Y-52.1%
ATR %4.5%
52w lowhigh53.7% off high

What Giant Biogene does

Chinese biotech skincare company specializing in recombinant collagen skincare and medical dressing products, under the Kefumei brand.

Sells mostly through online storefronts, driven by heavy spending on livestream and social-media marketing, with the Kefumei brand carrying most revenue and the products positioned as medical-grade rather than ordinary cosmetics. Founder Fan Daidi, a university professor, leads the company.

In one line: A Chinese bio-skincare innovator.

Products and services

  • Recombinant collagen skincare
  • Medical-grade dressings/wound care
  • Functional skincare

Customers

  • Chinese consumers via e-commerce and dermatology c

Where it sits in the supply chain

  • Consumer Staples/Healthcare
  • Bio-skincare
  • Recombinant collagen products

What could go right

  • Growth of medical-grade/functional skincare in China

What could go wrong

  • Regulatory scrutiny of medical-claim marketing
  • Competitive bio-skincare category

Moat: narrow (IP / patents, brand). Proprietary recombinant collagen technology and patents differentiate it from conventional skincare brands.

Headquarters: Jinan, Shandong, China · Founded: 2000 · Employees: 2,201

Named competitors

Giant Biogene at a glance

Size Giant Biogene (2367.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $2.47B, the 364th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$19.13 on 18 Nov 2026.

Performance Over six months the shares fell 31.7%, against +7.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 9.7% over the last twelve months (peer median +2.3%); the operating margin is 31.7% (peer median 10.6%).

Valuation It trades at 8.6× forward earnings against a peer median of 23.2× (cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -46 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 58.4 points above its cost of capital (9.8% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 1092367.HK 68
Six months, rebased to 100: Giant Biogene against the median of its 20 peers (local-currency closes).

Giant Biogene financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$5.96BHK$5.98BHK$6.01BHK$3.89BHK$2.75B
Revenue growth—0%+54%+42%—
Gross profitHK$4.71BHK$4.81BHK$4.93BHK$3.26BHK$2.32B
EBITDAHK$1.99BHK$2.39BHK$2.53BHK$1.82BHK$1.35B
Net incomeHK$1.87BHK$2.08BHK$2.24BHK$1.60BHK$1.17B
Free cash flowHK$2.05BHK$1.65BHK$2.07BHK$1.62BHK$921M
Capital expenditureHK$293MHK$480MHK$268MHK$252MHK$178M
Total debtn/aHK$10.8MHK$7.14MHK$3.00MHK$2.90M

Quarterly statements and history in the cockpit →

Giant Biogene competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%192820300888GILLETTEPGHH2698051900492260360569931618904927ENR496710447956ITP300957COTY6039832367.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Giant Biogene is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×192820300888GILLETTEPGHH2698051900492260360569931618904927EMAMILTDENR496710447956300957COTY6039832367.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Giant Biogene is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%300888GILLETTEPGHH26980519006036051618904927EMAMILTD49671044ITP300957COTY2367.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Giant Biogene is the large dot.

Giant Biogene competitors and peer comparison

Head to head with its named competitors (2367.HK vs 1318.HK vs 688363.SS vs 603605.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Giant Biogene 2367.HK$2.47B-32%-10%32%8.6×-10.7%
Mao Geping Cosmetics 1318.HK$4.67B-8%+32%31%14.3×4.1%
Bloomage Biotechnology 688363.SS$2.27B-21%-22%5%52.0×19.0%
Proya Cosmetics 603605.SS$2.87B-13%+2%13%10.9×-5.3%

How Giant Biogene compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Giant Biogene against its 20 peers (data as of 18 Nov 2026)
Measure2367.HKPeer medianRank in peer set
1-month return-16.8%+3.5%2nd lowest of 21
6-month return-31.7%+7.1%2nd lowest of 21
Distance from 52-week high-53.7%-22.4%lowest of 21
Revenue growth (TTM)-9.7%+2.3%lowest of 21
Operating margin31.7%10.6%highest of 21
Forward P/E8.6×23.2×cheapest of 21
Growth the price implies (Req g, 7 yrs)-10.7%0.5%least demanding of 17
Growth delivered (Del g)+34.9%+5.1%highest of 17
Hurdle (Req g minus delivered)-45.6 pp-3.3 ppleast demanding of 17
ROIC minus cost of capital+58.4 pp+5.1 pp2nd highest of 20
EV / EBITDA5.4×12.3×cheapest of 16
Net debt / EBITDA-4.3×-0.6×2nd least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Giant Biogene 2367.HKHong Kong$2.47B-32%-10%32%8.6×-10.7%+34.9%
Cosmax 192820.KSSouth Korea$2.51B+53%+25%8%18.8×n/an/a
Winner Medical 300888.SZChina$2.53B-6%+4%11%19.9×-5.2%-2.6%
Gillette India GILLETTE.NSIndia$2.53B-5%+8%28%37.1×14.9%+13.0%
Procter & Gamble Hygiene & Health Care PGHH.NSIndia$2.37B-30%-2%24%27.0×21.2%+7.4%
Softcare 2698.HKHong Kong$2.20B+5%+25%25%14.4×9.1%+20.9%
LG H&h 051900.KSSouth Korea$2.81B-14%-3%3%23.1×-4.6%-4.1%
KOSE 4922.TJapan$2.16B+16%+4%5%29.9×n/an/a
Proya Cosmetics 603605.SSChina$2.87B-13%+2%13%10.9×-5.3%+23.1%
Blue Moon 6993.HKHong Kong$2.07B-4%-2%-2%103.3×n/an/a
Kolmar Korea 161890.KSSouth Korea$2.05B+14%+16%10%14.3×-1.6%+15.5%
Pola Orbis 4927.TJapan$2.04B+15%+1%11%30.6×-2.0%-0.7%
Emami EMAMILTD.NSIndia$1.94B-5%+13%20%23.4×21.5%+5.6%
Energizer ENRUnited States$1.94B+71%0%17%9.1×-5.1%-0.5%
Kobayashi Pharmaceutical 4967.TJapan$3.25B+20%+2%6%48.7×18.0%+1.9%
Hengan Int'l 1044.HKHong Kong$3.27B-12%+2%11%9.1×-8.2%-0.1%
Pigeon 7956.TJapan$1.76B+26%+8%13%27.9×-2.4%+1.9%
Interparfums ITP.PAFrance$3.49B+66%-4%18%26.9×15.6%+19.6%
Yunnan Botanee Bio-Technology 300957.SZChina$1.69B-33%+7%9%19.1×2.6%+15.3%
Coty COTYUnited States$3.71B+116%0%5%13.5×9.8%+4.6%
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a

Questions

Who are Giant Biogene's main competitors?
Named competitors: Mao Geping Cosmetics (1318.HK), Bloomage Biotech (688363.SS), Proya Cosmetics (603605.SS). The cockpit's measured peer set (industry) also includes Cosmax (192820.KS), Winner Medical (300888.SZ), Gillette India (GILLETTE.NS), Procter & Gamble Hygiene & Health Care (PGHH.NS), Softcare (2698.HK), LG H&h (051900.KS).
Is Giant Biogene expensive compared with its peers?
On forward p/e it trades at 8.6× against a peer median of 23.2×, cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -46 pp: the price already allows for a slowdown.
How has Giant Biogene stock performed?
Over six months to 18 Nov 2026 the shares returned -31.7% against +7.1% for the median peer; over one year -52.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.